SELLAS Life Sciences
112 hedge funds and large institutions have $134M invested in SELLAS Life Sciences in 2025 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 50 increasing their positions, 18 reducing their positions, and 9 closing their positions.
802% more call options, than puts
Call options by funds: $81.5M | Put options by funds: $9.04M
211% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 9
178% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 18
152% more capital invested
Capital invested by funds: $53.1M → $134M (+$80.7M)
19% more funds holding
Funds holding: 94 → 112 (+18)
6.39% less ownership
Funds ownership: 31.28% → 24.89% (-6.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.16M |
| 3 |
Millennium Management
New York
|
+$2.09M |
| 4 |
Two Sigma Investments
New York
|
+$1.82M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$9.71M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.98M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$999K |
| 4 |
Renaissance Technologies
New York
|
-$470K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$378K |
SLS Hedge Fund Activity: Q4 2025 in Review
112 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q4 2025, worth a combined $134M — up 152% from $53.1M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new SLS positions and 9 closed out — a net gain of 19 holders — while 50 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $3.6M. The largest seller was Anson Funds Management, exiting entirely with an estimated $9.71M sold.
- 112 institutional investors held SELLAS Life Sciences (SLS) as of Q4 2025, up from 94 in Q3 2025.
- Funds reported $134M of SELLAS Life Sciences stock for Q4 2025, up 152% quarter-over-quarter.
- 28 funds opened new SELLAS Life Sciences positions in Q4 2025 and 9 closed out, a net change of +19 holders.
- The largest SELLAS Life Sciences buyer in Q4 2025 was BlackRock, an estimated $3.6M added.
- The largest SELLAS Life Sciences seller in Q4 2025 was Anson Funds Management, an estimated $9.71M sold.
Based on aggregated 13F filings for Q4 2025.